Avenue Therapeutics, Inc. (NASDAQ:ATXI) Short Interest Down 35.9% in December

Avenue Therapeutics, Inc. (NASDAQ:ATXI) was the target of a large decline in short interest during the month of December. As of December 31st, there was short interest totalling 22,500 shares, a decline of 35.9% from the December 15th total of 35,100 shares. Currently, 1.3% of the shares of the stock are short sold. Based on an average trading volume of 49,600 shares, the days-to-cover ratio is currently 0.5 days.

Avenue Therapeutics Trading Down 7.9 %

Shares of ATXI traded down $0.15 during midday trading on Thursday, hitting $1.75. The stock had a trading volume of 69,234 shares, compared to its average volume of 85,473. Avenue Therapeutics has a fifty-two week low of $1.60 and a fifty-two week high of $15.00. The business has a 50-day simple moving average of $1.92 and a two-hundred day simple moving average of $2.41. The firm has a market cap of $3.59 million, a P/E ratio of 0.10 and a beta of -0.27.

Institutional Investors Weigh In On Avenue Therapeutics

An institutional investor recently bought a new position in Avenue Therapeutics stock. Armistice Capital LLC purchased a new position in shares of Avenue Therapeutics, Inc. (NASDAQ:ATXI) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 75,000 shares of the company’s stock, valued at approximately $262,000. Armistice Capital LLC owned approximately 7.97% of Avenue Therapeutics as of its most recent filing with the SEC. 17.34% of the stock is currently owned by institutional investors.

Avenue Therapeutics Company Profile

Avenue Therapeutics, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.